The paper by Pansoy and coworkers investigates the effects of the aryl hydrocarbon receptor (AHR) ligand 3-methylcholanthrene (3MC) on recruitment of the AHR complex to human promoters in T47D breast cancer cells. The results are particularly important because they can be compared with a prior study using the potent AHR ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in the same cell line. The chromatin immunoprecipitation and promoterfocused microarrays (ChIP-chip) demonstrated that after treatment of T47D cells with 1mM 3MC, there were 241 AHR-3MC bound regions and many of these contained AHR-responsive elements. However, they also observed interactions with regions that do not contain these responsive elements, and subsequent analysis of selected target genes show that 3MC-dependent AHR binding did not necessarily predict Ah-responsiveness because induction, repression, and no effects were observed. A prior study with TCDD demonstrated that both 3MC and TCDD induced AHR binding to 127 common regions; however, there were significant differences in ligand (3MC vs. TCDD)-dependent AHR bound regions. The results illustrate the complexity of AHR signaling and also demonstrate that compared with TCDD as a reference ligand, 3MC is a selective AHR modulator.
The aryl hydrocarbon receptor (AHR) is a ligand-activated nuclear transcription factor that forms a heterodimer with the AHR nuclear translocator protein. This complex binds to xenobiotic response elements (XREs) in target gene promoters to activate transcription (Gu et al., 2000) . 2, 3, 7, was initially identified as a high-affinity ligand for the AHR, and aryl hydrocarbons such as 3-methylcholanthrene (3MC), benzo [a] pyrene (BaP), and other polynuclear aromatic hydrocarbons (PAHs) also bind and activate the AHR complex. Both TCDD and 3MC induce CYP1A1 and other biochemical responses associated with activation of the AHR complex; however, the toxic effects of TCDD and related halogenated aromatics are generally not observed for 3MC and related PAHs. Differences between TCDD, PAHs, and other AHR ligands have been explained not only by differences in their AHR-binding affinities and rate of metabolism but also by the persistent occupation of the AHR by TCDD compared with 3MC and other PAHs. The paper by Pansoy et al. (2010) and a prior study by the same group (Ahmed et al., 2009) have probed the differences between 3MC and TCDD by comparing their ligand-dependent recruitment of the AHR complex to chromatin regions and gene promoters in Ah-responsive T47D human breast cancer cells.
3MC VERSUS TCDD: DIFFERENTIAL RECRUITMENT OF THE AHR COMPLEX TO HUMAN GENE PROMOTERS
In this study, T47D cells were treated with 3MC for 1 h and analyzed by ChIP-chip assays using Affymetrix human 1.0R promoter tiling arrays. Analysis of the data showed the 3MC and TCDD treatment induced AHR binding to 241 (AHR 3MC ) and 286 (AHR TCDD ) regions, respectively, and 53% of AHR 3MC and 44% of the AHR TCDD regions were common for both ligands. Moreover, by ranking the AHR 3MC binding sites, the authors showed that ''100% of the top 50 and 87% of the top 100 AHR 3MC bound were also bound by AHR TCDD .'' Using another approach, Pansoy et al. (2010) showed that among the 214 and 259 putative target genes for 3MC and TCDD, respectively, 56% (120/214) (for 3MC) and 46% (120/ 259) (for TCDD) were in common. In more detailed studies with a subset of genes, there also was overlap in the inducibility of several genes by 3MC and TCDD and it was also observed that in treated cells, 3MC also decreased or did not affect expression of genes, which contained regions that were enriched by AHR binding. Another important observation was that~50% of the AHR-binding sites contained an Ahresponsive element, and similar results were reported for TCDD in mouse hepatoma Hepa1c1c7 cells (Kinehara et al., 2008) . Although this data and previous studies demonstrate considerable overlap in the in vitro effects of two prototypical AHR ligands (TCDD and 3MC) with different AHR-binding affinities, the results also indicate that within the relatively short time frame of this in vitro study, there were highly significant differences between 3MC and TCDD. Some of these ligand-dependent variables include AHR complexbinding regions, target genes, binding sites (AhRE vs. nonAhRE), and increased Ah-responsiveness (to 3MC but not to TCDD) after an initial treatment of T47D cells with 3MC or TCDD for 24 h. Other possible ligand-dependent differences not fully investigated by Pansoy et al. (2010) may be gene promoter-specific oscillatory recruitment of the AHR complex, recruitment of ERa to Ah-responsive gene promoters, and histone modifications. The observed and potential liganddependent differences between 3MC and TCDD and those previously observed for BaP and TCDD (Kinehara et al., 2008) illustrate this complexity of AHR-mediated mechanisms of action for structurally diverse AHR ligands. These observations are consistent with the concept that AHR ligands are selective receptor modulators.
AHR-ACTIVE COMPOUNDS ARE SELECTIVE AhR MODULATORS
Steroid hormone receptors and other members of the nuclear receptor superfamily are important drug target where various receptor-active compounds exhibit tissue-specific receptor agonist or antagonist activities. For example, selective estrogen receptor (ER) modulators (SERMs) such as tamoxifen exhibit species-/tissue-specific ER agonist and antagonist activity, and the use of this drug for endocrine therapy of mammary cancer is because of its ER antagonist activity in breast cancer (Jordan, 2009 ). The selective receptor agonist or antagonist activity of a ligand is because of the specific conformation of the ligandbound receptor, which in turn differentially interacts with promoter/enhancer DNA, modulates histones, and recruits different sets of nuclear cofactors required for transactivation (Katzenellenbogen et al., 1996) . Previous studies demonstrated that 6-methyl-1,3,8-trichlorodibenzofuran (MCDF) was a prototypical AHR antagonist and inhibited TCDD-induced CYP1A1 and several toxicities including porphyria, teratogenicity, and immunotoxicity in mice (Bannister et al., 1989) . In contrast, like TCDD, MCDF exhibited antiestrogenic activity in the rodent uterus and mammary tumors and human breast cancer cell lines (McDougal et al., 2001) . Moreover, in vitro DNA binding-proteolysis studies showed that MCDF and TCDD differentially bound the AhR, suggesting that MCDF was a selective AhR modulator (SAhRM). These biological differences between TCDD and MCDF have also been observed other AhR-active compounds. For example, both TCDD and 6-formylindolo [3,2-b] carbazole (FICZ) induce CYP1A1 and other biochemical responses in multiple tissues as AhR agonists, whereas TCDD induces and FICZ blocks T reg cells in a mouse model for experimental autoimmune encephalomyelitis (Quintana et al., 2008) . Pansoy et al. (2010) have used 3MC and a prior study on TCDD to provide molecular insights on ligand structure-dependent differences in the early events of AHR activation, chromatin binding and modifications, and transactivation. The significant similarities and differences between the effects of these ligands in the same cell line provides evidence that 3MC is also a SAhRM compared with TCDD, the most active AhR ligand which serves as the reference standard. The identification of chromatin regions that bind the AHR complex but do not contain the AHR-responsive element core sequence (GCGTG) is particularly intriguing and suggests that as yet unidentified, cis-elements may play a critical role in the SAhRM-like activity of AHR-active compounds. This observation is consistent with a study showing that 3MC and the polyphenolic compound quercetin were more potent than TCDD as inducers of paraoxonase-1 in a human hepatoma cell line (Gouedard et al., 2004) . AHR ligand potency differences were because of the ''active'' cis-elements (GCGGG) in the paraoxonase-1 gene promoter, which differ from the XRE core GCGTG sequence. Moreover, it is also possible that the AhR complex which is formed in T47D cells treated with MC is not directly bound to promoter DNA but to other DNA-bound transcription factors to form AhR-protein-DNA complexes.
Results of chromatin-binding studies (Ahmed et al., 2009; Pansoy et al., 2010) show that the AhR complex bears a distinct similarity to steroid hormone receptors and particularly the ER. Both the AhR and the ER exhibit liganddependent differences in their chromatin-binding sites, and for the ER, there is extensive evidence for direct binding to consensus and nonconsensus palindromic estrogen responsive elements (EREs) and ERE half-sites and for indirect binding via ER-protein-DNA complexes (Safe and Kim, 2008) . Moreover, like the ER, there is evidence for the promiscuity of AHR ligands, which includes a growing list of structurally diverse industrial compounds and by-products, environmental contaminants, phytochemicals, pharmaceutical agents, and endogenous biochemicals (Denison and Nagy, 2003) . In addition, several AHR agonists including BaP and 3MC interact with the ER (Abdelrahim et al., 2006) , and SERMs such as 4-hydroxytamoxifen are AHR agonists (Dusell et al., 2010) . Thus, the differences in the ligand-dependent interaction of the AHR with chromatin regions and specific gene promoters (Ahmed et al., 2009; Pansoy et al., 2010) is consistent with the ligand-dependent activation of different downstream responses and the inherent difficulty in predicting tissue-specific AHR agonist or antagonist activity of an AHRactive compound.
